Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 13, 2010

View Archived Issues

Roche discloses new selective inverse agonists of GABA(A) alpha5 receptor

Fraunhofer CMB begins phase I trial of H5N1 flu vaccine ppH5HA-I

Primary endpoint met in phase III ALLEGRO trial of oral laquinimod in MS

MN-100 inhibits growth of MM xenografts and alleviates tumor-associated immune suppression in vivo

Safety and preliminary antitumor activity of CEP-18770 reported in first-in-human study

CHR-2845 is well tolerated in first-in-human study

Adding ganitumab to exemestane or fulvestrant does not improve PFS in patients with breast cancer

Oncolytic agent S-110 shows promising preclinical results and advances into clinic

NeuroSearch describes new monoamine reuptake inhibitors

Xenon Pharma presents new blockers of voltage-gated sodium channels

First patient treated in phase I trial of LTX-315/GV-1001

New inhibitors of HCV serine protease NS3 discovered

FDA extends PDUFA target date for Benlysta

AiCuris completes phase II AIC-316 trial in patients with genital HSV-2 infection

BioMimetic Therapeutics begins enrollment in pilot trial of Augment rotator cuff graft

Merck & Co. divulges novel beta3-adrenoceptor agonists

Acorda Therapeutics begins phase I trial of GGF2 in heart failure

Apexigen and Centocor to collaborate on antibody discovery

Aoxing Pharma begins trial of sublingual buprenorphine/naloxone for opioid addiction

FDA clears Sequella's phase II trial of SQ-109 in duodenal ulcers associated with H. pylori

FDA orphan drug status for NeuroSTAT in traumatic brain injury

Prometheus Labs and UCLA study biological markers of mucosal healing in IBD

FDA lifts partial clinical hold on Valortim

BioVex begins phase III trial of OncoVex(GM-CSF) in head and neck cancer

BioDelivery Sciences initiates phase III program for BEMA-buprenorphine in chronic pain

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...